A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...
Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.
Ipsen (IPSEY) (IPSEF) shares traded higher in Paris on Wednesday after the U.S. FDA issued Breakthrough Therapy Designation ...
AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...
The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.
Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared ...
BURTON, MI, UNITED STATES, January 9, 2026 /EINPresswire.com/ -- Javelin Sciences, a pioneering certified biotechnology ...
Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured ...
Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and ...
A new kind of microscope is giving scientists a way to watch life inside cells with a clarity that feels almost unfair.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback